Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Pearce IP and 5 Leaders Ranked in IAM Patent 1000 2026 for AU and NZ Patent Prosecution and Litigation

by Pearce IP | May 29, 2026

Pearce IP and 5 Leaders Ranked in IAM Patent 1000 2026 for AU and NZ Patent Prosecution and Litigation. 2026 marks the sixth consecutive year of Pearce IP IAM Patent 1000 ranking in Australia, one of only 51 law firms this year. Pearce IP also been ranked by IAM Patent 1000 for New Zealand every year since launching in New Zealand in 2024 and is one of only 17 firms listed this year.

Pearce IP Ranked in 2027 ‘Best Law Firms Australia’ for Life Sciences & Intellectual Property

by Pearce IP | May 28, 2026

Pearce IP Ranked in 2027 ‘Best Law Firms Australia’ for Life Sciences & Intellectual Property. Published by Best Lawyers and underpinned by a rigorous methodology, the Best Law Firms – Australia is in its third edition. This is the second time Pearce IP has been recognised, with rankings in both Life Sciences and IP.

Pearce IP BioBlast® for the week ending 22 May 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | May 26, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 22 May 2026 are set out below…

Pearce IP’s Annual Australian Patent Case Review 2025 – Now Available

by Pearce IP | May 20, 2026

Pearce IP is pleased to release the Annual Australian Patent Case Review 2025, a comprehensive, expert analysis of all key patent decisions shaping the Australian legal landscape over the past year. Spanning 130 pages, this essential resource provides a complete overview of: All decisions delivered by the Federal Court of Australia, All decisions delivered by the Full Court on appeal & Significant decisions from the Australian Patent Office

Pearce IP BioBlast® for the week ending 15 May 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | May 19, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 15 May 2026 are set out below…

Pearce IP BioBlast® for the week ending 8 May 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | May 12, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 8 May 2026 are set out below…

Naomi Pearce & Pearce IP in Doyle’s Guide 2026 – Leading Contentious IP Law NSW

by Pearce IP | May 8, 2026

Pearce IP and its founder Naomi Pearce are ranked in the 2026 edition of Doyle’s Guide amongst a small number of leading NSW IP litigation firms and litigators. Naomi Pearce is one of 32 lawyers commended as NSW’s Leading Contentious Intellectual Property Lawyers.

Pearce IP BioBlast® for the week ending 1 May 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | May 5, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 1 May 2026 are set out below…

Inevitable Result and Clinical Trial Protocols

by Naomi Pearce, Helen Macpherson, Mathew Lucas PhD | Apr 30, 2026

On 9 February 2024, AU Pharma Pty Ltd filed a request for re-examination of the granted claims of Grunenthal’s AU2008241013 patent relating to titration methods of tapentadol. Tapentadol is a centrally acting analgesic known to be effective for the treatment of moderate to severe acute or chronic pain.

Pearce IP BioBlast® for the week ending 24 April 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | Apr 29, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 24 April 2026 are set out below…

A Litany of Errors… and Cipla’s Patent Reinstated

by Naomi Pearce, Helen Macpherson, Paul Johns | Apr 22, 2026

Cipla has defeated Teva’s and Bayer’s opposition to its application for an extension of time in which to pay the renewal fee on AU2003244799 for a combination of azelastine and steroids (the Cipla Patent), a combination used in the treatment of hay fever.

Pearce IP BioBlast® for the week ending 17 April 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | Apr 21, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 17 April 2026 are set out below…

Helen Macpherson Earns Dual Rankings in 2027 Best Lawyers In Australia™

by Pearce IP | Apr 16, 2026

Helen Macpherson, Pearce IP’s Executive Lawyer and Head of Litigation (Australia), has been recognised in 2027 The Best Lawyers in Australia™ for Intellectual Property Law and Life Sciences. Helen has been listed by Best Lawyers every year since 2017.

Pearce IP BioBlast® for the fortnight ending 10 April 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | Apr 14, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 10 April 2026 are set out below…

Pearce IP BioBlast® for the week ending 27 March 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | Mar 31, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 March 2026 are set out below…

Pearce IP BioBlast® for the week ending 20 March 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | Mar 24, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 March 2026 are set out below…

IP Australia Proposes Changes to “Streamline and Simplify” Australia’s IP System

by Mathew Lucas PhD, Paul Johns, Sally Paterson | Mar 19, 2026

IP Australia Proposes Changes to “Streamline and Simplify” Australia’s IP System. Earlier this month IP Australia issued a consultation paper seeking submissions on proposed reforms primarily to Australia’s current IP system. The consultation paper has been developed in conjunction with New Zealand Ministry of Business…

Pearce IP BioBlast® for the week ending 13 March 2026

by Naomi Pearce, Paul Johns, Maliha Hoque | Mar 17, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 March 2026 are set out below…

The One That Got Away – Aussie Fashion Designer Wins Trade Mark Stoush Against Katy Perry

by Helen Macpherson, Naomi Pearce | Mar 13, 2026

The One That Got Away – Aussie Fashion Designer Wins Trade Mark Stoush Against Katy Perry. The battle of the KATY(IE) PERRY trade marks has been ongoing since 2019, but thankfully the High Court of Australia has now settled the issue once and for all. In a decision handed down yesterday (11 March 2026)…

BREAKING NEWS – Australian High Court Grants Leave to Appeal to Otsuka in PTE Dispute

by Naomi Pearce, Paul Johns, Helen Macpherson | Mar 12, 2026

BREAKING NEWS: The High Court of Australia today granted special leave to Otsuka to appeal the decision of the Full Federal Court in Otsuka v Sun Pharma [2025] FCAFC 161 in which it unanimously held that pharmaceutical formulation patents are ineligible for patent term extension (PTE) in Australia.

Pearce IP BioBlast® for the week ending 6 March 2026

by Naomi Pearce, Paul Johns, Maliha Hoque | Mar 10, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 6 March 2026 are set out below…

FORXIGA® Injunction Breaks New Ground

by Naomi Pearce, Paul Johns, Helen Macpherson | Mar 4, 2026

FORXIGA® Injunction Breaks New Ground. As we have previously reported, Justice Downes of the Federal Court of Australia has set a new record for expedition in the patent dispute between AstraZeneca and Pharmacor, relating to the latter’s generic dapagliflozin.

Pearce IP BioBlast® for the week ending 27 February 2026

by Naomi Pearce, Chantal Savage, Maliha Hoque | Mar 3, 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 February 2026 are set out below…

HOT TOPIC | A Seismic Shift in Australian Pharma Patent Strategy | Fault Lines Emerge in PTEs and Preliminary Injunctions

by Naomi Pearce | Feb 27, 2026

HOT TOPIC | A Seismic Shift in Australian Pharma Patent Strategy | Fault Lines Emerge in PTEs and Preliminary Injunctions. Recent developments in Australian law and practice concerning Patent Term Extensions (PTEs) and preliminary injunctions (PIs) will shake up the pharmaceutical market. For originators, generics and biosimilar sponsors alike…

« Older Entries

Next Entries »

Recent BioBlast® Updates

Health Canada Approves Biocon’s Ustekinumab Autoinjector

Jul 29, 2026

On 29 July 2026, Biocon announced that it has received Notice of Compliance (NOC) approval from Health Canada for ustekinumab (Yesintek®)…

First Wave of Generic Ozempic® (Semaglutide) Approvals Underway in South America with Sandoz/Adalvo’s Owozy®

Jul 29, 2026

On 29 July 2026, Sandoz announced that Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA) has approved Owozy® (semaglutide), a…

EPO Board of Appeal Upholds Revocation of BMS’ Opdivo® (Nivolumab) Patent

Jul 29, 2026

On 29 July 2026, the EPO published the Board of Appeal’s decision of 6 May 2026 upholding the Opposition Division’s 13 March 2024…

New Indication Alert: AstraZeneca/Daiichi’s Enhertu® (Trastuzumab Deruxtecan) + THP Approved in India for HER2-Positive Breast Cancer

Jul 28, 2026

On 28 July 2026, AstraZeneca announced that India’s Central Drugs Standard Control Organisation (CDSCO) has approved an indication…

Roche Sues Biocon on 28 US Pertuzumab Patents

Jul 26, 2026

On 26 July 2026, Roche and Genentech commenced BPCIA proceedings in the US District Court in New Jersey against Biocon in relation…

Celltrion Submits EU Application for Biosimilar to Novartis’ Cosentyx® (Secukinumab)

Jul 24, 2026

On 24 July 2026, Celltrion announced that it has submitted an application for marketing approval to the European Medicines Agency (EMA) for CT-P55, biosimilar to Novartis’ Cosentyx® (secukinumab), seeking all approved reference indications.

July 2026 CHMP Positive Opinions Include CuraTeQ’s Biosimilar to Amgen’s Neulasta® (Pegfilgrastim) and Roche’s Susvimo® (Ranibizumab)

Jul 24, 2026

On 24 July 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) announced the outcomes of its July 2026 meeting, including positive opinions for one biosimilar and two biopharmaceuticals.

FDA Approves Outlook Therapeutics’ Lytenava™ (Ophthalmic Bevacizumab) Following 3 CRLs

Jul 24, 2026

On 24 July 2026, Outlook Therapeutics announced that the FDA has approved ONS-5010/Lytenava™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD/wet AMD). Outlook expects Lytenava™ will be available to eligible patients in the US before the end of 2026.

Samsung Bioepis Publishes Q3/2026 US Biosimilar Market Report – Ustekinumab Market Share at 42%

Jul 23, 2026

On 23 July 2026, Samsung Bioepis published the 14th edition of its US Biosimilar Market Report, which has been released every quarter since April 2023.

Accord BioPharma Launches Osvyrti® & Jubereq® (Denosumab), Biosimilars to Amgen’s Prolia® & Xgeva®, in US

Jul 23, 2026

On 23 July 2026, Accord BioPharma announced its US launch of Osvyrti® and Jubereq® (denosumab), interchangeable biosimilars to Amgen’s Prolia® and Xgeva®, respectively. The denosumab biosimilars are the first products of Accord developed and manufactured “end to end” by its parent company, Intas Pharmaceuticals.

Medtas Launches Pharmacy Support Program in Australia for Wezlana®, Biosimilar to Janssen’s Stelara® (Ustekinumab)

Jul 22, 2026

On 22 July 2026, Medtas announced that it has launched a new in-pharmacy program (myMedtas-Care), following the 1 July 2026 listing of Wezlana®, biosimilar to Janssen’s Stelara® (ustekinumab), on the Australian Pharmaceutical Benefits Scheme (PBS).

Intas’ Biosimilar to Roche’s Kadcyla® (Trastuzumab Emtansine) Approved in India

Jul 22, 2026

On 22 July 2026, the Economic Times reported that Intas Pharmaceuticals has received marketing approval from India’s Central Drug Standard Control Organisation (CDSCO) for its trastuzumab emtansine biosimilar, referencing Roche’s Kadcyla®.

See Our BioBlast®

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here